+

PE20020409A1 - Derivados de 2h-tetrazol-5-il amida como agonistas de receptores de glutamato metabotropico - Google Patents

Derivados de 2h-tetrazol-5-il amida como agonistas de receptores de glutamato metabotropico

Info

Publication number
PE20020409A1
PE20020409A1 PE2001000693A PE2001000693A PE20020409A1 PE 20020409 A1 PE20020409 A1 PE 20020409A1 PE 2001000693 A PE2001000693 A PE 2001000693A PE 2001000693 A PE2001000693 A PE 2001000693A PE 20020409 A1 PE20020409 A1 PE 20020409A1
Authority
PE
Peru
Prior art keywords
alkyl
tetrazole
amide
agonists
tetrazol
Prior art date
Application number
PE2001000693A
Other languages
English (en)
Inventor
Eric Vieira
Vincent Mutel
Synese Jolidon
Juergen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20020409A1 publication Critical patent/PE20020409A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE 2H-TETRAZOL-5-IL-AMIDA DE FORMULA I, DONDE R1 ES H, ALQUILO, (CH2)n-CF3, (CH2)n-CHF2, (CH2)n-CN, ENTRE OTROS; R2 ES H, ALQUILO, ALCOXILO, HALOGENO, CO-ALQUILO, COOH, COO-ALQUILO, NR3R4, ENTRE OTROS; R3 Y R4 SON H, ALQUILO; X ES O, S, CH2, OCH2; n ES 0-4. SON COMPUESTOS PREFERIDOS N-(2-METIL-2H-TETRAZOL-5-IL)-2,2-DIFENIL-ACETAMIDA; (2-METIL-2H-TETRAZOL-5-IL)-AMIDA DEL ACIDO 9H-XANTEN-9-CARBOXILICO; N-(2-ISOPROPIL-2H-TETRAZOL-5-IL)-2,2-DIFENIL-ACETAMIDA, 2,2-DIFENIL-N-[2(2,2,2-TRIFLUORO-ETIL)-2H-TETRAZOL-5-IL]-ACETAMIDA, ENTRE OTROS; TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS SON AGONISTAS DE RECEPTORES DE GLUTAMATO METABOTROPICO DEL GRUPO I mGLU Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE PSICOSIS, ESQUIZOFRENIA, ENFERMEDAD DE ALZHEIMER, TRASTOROS DEL CONOCIMIENTO Y DEFICITS DE MEMORIA, DOLOR AGUDO O CRONICO
PE2001000693A 2000-07-13 2001-07-11 Derivados de 2h-tetrazol-5-il amida como agonistas de receptores de glutamato metabotropico PE20020409A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00115170 2000-07-13

Publications (1)

Publication Number Publication Date
PE20020409A1 true PE20020409A1 (es) 2002-05-21

Family

ID=8169240

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000693A PE20020409A1 (es) 2000-07-13 2001-07-11 Derivados de 2h-tetrazol-5-il amida como agonistas de receptores de glutamato metabotropico

Country Status (19)

Country Link
US (1) US6399641B1 (es)
EP (1) EP1303499B1 (es)
JP (1) JP3971298B2 (es)
KR (1) KR100504292B1 (es)
CN (1) CN1214017C (es)
AR (1) AR029706A1 (es)
AT (1) ATE332895T1 (es)
AU (2) AU7847201A (es)
BR (1) BR0112465A (es)
CA (1) CA2415673A1 (es)
DE (1) DE60121447T2 (es)
DK (1) DK1303499T3 (es)
ES (1) ES2267797T3 (es)
MX (1) MXPA03000221A (es)
PA (1) PA8521901A1 (es)
PE (1) PE20020409A1 (es)
PT (1) PT1303499E (es)
WO (1) WO2002006254A1 (es)
ZA (1) ZA200210157B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY174572A (en) 2003-08-06 2020-04-27 Firmenich Incorporated Novel flavors, flavor modifiers, tastants, taste enhancers, umani or sweet tastants, and/or enhancers and use thereof
EP1726585A4 (en) * 2004-03-05 2009-07-15 Banyu Pharma Co Ltd DIARYLSUBSTITUTED FIVE-GLOSS HETEROCYCLUS DERIVAT
MX2007009388A (es) 2005-02-04 2007-09-25 Senomyx Inc Compuestos que comprenden porciones heteroarilo unidas y su uso como modificadores del sabor unami, saborizantes y mejoradores del sabor para composiciones comestibles.
TW200715993A (en) 2005-06-15 2007-05-01 Senomyx Inc Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
DK2010009T3 (en) 2006-04-21 2017-10-02 Senomyx Inc PROCEDURES FOR THE PREPARATION OF SOLID FLAVOR COMPOSITIONS
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2093234A1 (en) 2008-02-08 2009-08-26 Nutrinova Nutrition Specialties & Food Ingredients GmbH Oligopeptides for use as taste modulators
TWI429404B (zh) 2008-03-03 2014-03-11 Senomyx Inc 異山梨醇衍生物及彼等作為風味改良劑、促味劑及促味增強劑之用途
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1343827A (en) * 1971-06-15 1974-01-16 Science Union & Cie Acylaminotetrazoles and process for preparing them
DE4129742A1 (de) * 1991-09-06 1993-03-11 Bayer Ag Heterocyclisch substituierte chinolylmethoxy-phenylacetamide
GB9626151D0 (en) * 1996-12-17 1997-02-05 Lilly Industries Ltd Pharmaceutical compounds
DE69832302D1 (de) * 1997-12-10 2005-12-15 Nps Pharma Inc Antikonvulsive und zns-aktive bis-fluoralkylamide
US6548522B1 (en) * 1999-10-12 2003-04-15 Hoffmann-La Roche Inc. Method for treating conditions related to the glutamate receptor using carboxylic acid amide derivatives

Also Published As

Publication number Publication date
EP1303499B1 (en) 2006-07-12
EP1303499A1 (en) 2003-04-23
KR100504292B1 (ko) 2005-07-28
US20020022648A1 (en) 2002-02-21
BR0112465A (pt) 2003-07-22
DE60121447D1 (de) 2006-08-24
AR029706A1 (es) 2003-07-10
PT1303499E (pt) 2006-11-30
ES2267797T3 (es) 2007-03-16
CA2415673A1 (en) 2002-01-24
KR20030016390A (ko) 2003-02-26
ZA200210157B (en) 2004-03-15
DK1303499T3 (da) 2006-10-30
JP2004504308A (ja) 2004-02-12
CN1214017C (zh) 2005-08-10
CN1441791A (zh) 2003-09-10
AU2001278472B2 (en) 2006-08-03
MXPA03000221A (es) 2003-06-06
PA8521901A1 (es) 2002-04-25
JP3971298B2 (ja) 2007-09-05
ATE332895T1 (de) 2006-08-15
DE60121447T2 (de) 2007-02-01
WO2002006254A1 (en) 2002-01-24
AU7847201A (en) 2002-01-30
US6399641B1 (en) 2002-06-04

Similar Documents

Publication Publication Date Title
PE20020409A1 (es) Derivados de 2h-tetrazol-5-il amida como agonistas de receptores de glutamato metabotropico
PE20021005A1 (es) Quinazolinas como inhibidores de mmp-13
NO981496D0 (no) Imidazolderivater med affinitet for <alfa> 2 reseptoraktivitet
PE20020332A1 (es) Derivados de 4-fenil-piridina como antagonistas de receptores de neuroquinina nk-1
HRP20050708A2 (en) Piperidine-benzenesulfonamide derivatives
PE59099A1 (es) Nuevos derivados del acido hexanoico
PE20001467A1 (es) Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina
KR930005995A (ko) 벤즈아닐리드 유도체
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
EE9700283A (et) Bensimidasooli ühendid, nimetatud ühendeid sisaldavad farmatseutilised kompositsioonid ja nende kasutamine
PE121699A1 (es) Heterociclos biciclicos disustituidos como inhibidores de la trombina
RU2009136592A (ru) Терапевтические агенты
RU2014113679A (ru) N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1
ES8501358A1 (es) Un procedimiento para la prepracion de eteres 2-aminoetilicos.
PE20030447A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol-3-il)-sustituidos y su obtencion
PE20021158A1 (es) Derivados de sulfonamida como antagonistas del receptor de bradiquinina
DK0586806T3 (da) Anvendelse af 2-(N-(2-aminoethyl)-amino)-eddike-syrederivater til behandling af sygdomme, der er betinget af den ikke-enzym
ES2032384T3 (es) Procedimiento para preparar derivados de carboxamidas.
RU2007125660A (ru) Фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофамина-d2 и ингибирования повторного поглощения серотонина
UY26051A1 (es) Derivados de bifenilos antagonistas del receptor de nk-1
PE20010153A1 (es) Derivados de 4-fenil-pirimidina como antagonistas del receptor de neuroquinina
PE20060630A1 (es) Amidas sustituidas de acido tienopirrolcarboxilico, amidas del acido pirrolotiazolcarboxilico y analogos relacionados como inhibidores de la caseina cinasa ie
EA200001184A1 (ru) Фенилсульфонамидфенилэтиламины, полезные в качестве допаминовых рецепторов
RU2002113771A (ru) Новые антагонисты рецепторов интерлейкина-8
PE20021154A1 (es) Derivados de 4-aminopirimidina como antagonistas del receptor metabotropico de glutamato

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载